Shots: AstraZeneca will evaluate the combination of Monalizumab with Cetuximab for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with the anticipated onset of […]readmore
Tags : Innate Pharma
Shots: AZ gains complete rights to monalizumab (Anti-NKG2A), also gains option rights to IPH5201 as well as 4 preclinical immuno-oncology molecules Innate gains US and EU rights of Lumoxiti approved […]readmore